Fresenius

DGAP-News: Fresenius Medical Care AG & Co. KGaA anticipates significant negative impact on 2021 net income from accelerated COVID-19 related excess mortality of dialysis patients; confirms mid-term targets

Retrieved on: 
Monday, February 1, 2021

DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Forecast

Key Points: 
  • DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Forecast
    Fresenius Medical Care AG & Co. KGaA anticipates significant negative impact on 2021 net income from accelerated COVID-19 related excess mortality of dialysis patients; confirms mid-term targets
    The issuer is solely responsible for the content of this announcement.
  • Despite those negative impacts of the COVID-19 pandemic, Fresenius Medical Care has achieved - based on the preliminary and unaudited financials - its revenue target and slightly exceeded its net income [1] targets for 2020 [2] .
  • Through its network of 4,073 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 349,167 patients around the globe.
  • Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius Medical Care North America Enhances Nationwide Distribution of Home Dialysis Machines and Supplies with Descartes Last Mile Delivery Solution

Retrieved on: 
Monday, February 1, 2021

Descartes last mile delivery solution provides an end-to-end platform for home and last mile delivery operations.

Key Points: 
  • Descartes last mile delivery solution provides an end-to-end platform for home and last mile delivery operations.
  • Using advanced continuous optimization technology, Descartes last mile delivery solution takes committed appointments and improves route productivity, which generates additional delivery capacity and reduces costs.
  • Were pleased to help Fresenius Medical Care North America make the distribution of its services and equipment more responsive and efficient, said James Wee, Vice President at Descartes.
  • Fresenius Medical Care North America (FMCNA) is the premier healthcare company focused on providing the highest quality care to people with renal and other chronic conditions.

RenalSense Announces Distribution Agreement in Israel with Medtechnica

Retrieved on: 
Monday, January 25, 2021

JERUSALEM, Jan. 25, 2021 /PRNewswire/ --RenalSense, a leading company in real-time renal diagnostics, today announced a distribution agreement with Medtechnica, Israel's largest distributor of medical equipment and health services.Medtechnica will market RenalSense's Clarity RMScritical care monitoring system to hospitals throughout Israel.

Key Points: 
  • JERUSALEM, Jan. 25, 2021 /PRNewswire/ --RenalSense, a leading company in real-time renal diagnostics, today announced a distribution agreement with Medtechnica, Israel's largest distributor of medical equipment and health services.Medtechnica will market RenalSense's Clarity RMScritical care monitoring system to hospitals throughout Israel.
  • RenalSense is currently in discussions with additional partners regarding distribution agreements for other key markets.
  • Medtechnica, founded in 1953, is the largest distributor of medical equipment and health services in Israel.
  • Manufacturers represented by Medtechnica include Fresenius Kabi, Philips, Boston Scientific, Getinge, Masimo, Hologic, Elekta, J&J, Hill-Rom among other blue chip companies.

CytoSorbents Announces Approval of CytoSorb® in Korea in Collaboration with Partner Fresenius Medical Care

Retrieved on: 
Tuesday, January 19, 2021

CytoSorbents (NASDAQ:CTSO) Announces Korean Approval of CytoSorb, a Treatment of Deadly Cytokine Storm and Inflammation

Key Points: 
  • CytoSorbents (NASDAQ:CTSO) Announces Korean Approval of CytoSorb, a Treatment of Deadly Cytokine Storm and Inflammation
    Ms. Clare Kim, Managing Director of Fresenius Medical Care Korea commented, "In Korea, the sepsis mortality rate and incidence have increased steadily and remains a major problem in critical care.
  • Under these circumstances, we are pleased to introduce the cytokine adsorber, CytoSorb, to healthcare professionals and patients in Korea.
  • Fresenius Medical Care Korea remains committed to having a positive impact on the care of severely ill patients with CytoSorb."
  • Mr.Vincent Capponi, President and Chief Operating Officer of CytoSorbents, stated, "We are pleased to have successfully achieved approval of CytoSorb inKorea, in cooperation with our partner Fresenius Medical Care.

Fresenius Medical Care's Frenova enrolls patients in initiative to build world's largest genomic registry targeting kidney disease

Retrieved on: 
Monday, January 11, 2021

The renal-focused genomic registry represents a new business line within Frenova, which is based in Fresenius Medical Care's Global Medical Office.

Key Points: 
  • The renal-focused genomic registry represents a new business line within Frenova, which is based in Fresenius Medical Care's Global Medical Office.
  • Frenova's new genomic registry will contain genetic sequencing data from chronic kidney disease patients worldwide, which will be used by researchers to improve the understanding of kidney disease.
  • Frenova developed the registry after researchers identified the lack of a large-scale, renal-focused registry of genomic and clinical data as a major impediment to kidney disease research.
  • Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius Kabi Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP Due to the Presence of Particulate Matter

Retrieved on: 
Friday, January 8, 2021

Distributors should notify their customers and direct them to quarantine and discontinue distributing or dispensing the affected lot, and to return the product to Fresenius Kabi.

Key Points: 
  • Distributors should notify their customers and direct them to quarantine and discontinue distributing or dispensing the affected lot, and to return the product to Fresenius Kabi.
  • The recall letter and response form are available at https://www.fresenius-kabi.com/us/pharmaceutical-product-updates .
  • Customers with questions regarding this recall may contact Fresenius Kabi at 1-866-716-2459 Monday through Friday, during the hours of 8:00 a.m. to 5:00 p.m. Central Time.
  • Fresenius Kabi ( www.fresenius-kabi.com/us ) is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition.

High prevalence of hospital malnutrition associated with poor clinical outcomes

Retrieved on: 
Monday, December 14, 2020

The review also revealed that malnutrition is frequently linked to poor clinical outcomes and increased healthcare costs bringing to light a critical unmet patient need within the region.

Key Points: 
  • The review also revealed that malnutrition is frequently linked to poor clinical outcomes and increased healthcare costs bringing to light a critical unmet patient need within the region.
  • Two of the reviewed studies investigated the economic consequences of malnutrition, both found a clear association between hospital malnutrition and increased hospitalization costs.
  • Articles reporting data on the prevalence, clinical consequences, or economic costs of hospital malnutrition in an adult inpatient population with a sample size 30 were included in the analysis.
  • Launched in 2015 by Fresenius Kabi, 'United for clinical nutrition' aims to overcome hospital malnutrition around the world.

Sargent & Greenleaf Names Steven Samaan as Vice President of Global Supply Chain & Logistics

Retrieved on: 
Thursday, December 10, 2020

NICHOLASVILLE, Ky., Dec. 10, 2020 /PRNewswire-PRWeb/ -- A world leader in high security locks and locking systems, Sargent & Greenleaf Inc. (S&G) welcomes Steven Samaan as its new vice president of global supply chain & logistics.

Key Points: 
  • NICHOLASVILLE, Ky., Dec. 10, 2020 /PRNewswire-PRWeb/ -- A world leader in high security locks and locking systems, Sargent & Greenleaf Inc. (S&G) welcomes Steven Samaan as its new vice president of global supply chain & logistics.
  • "We are thrilled to welcome Steven to our S&G team," says Mark LeMire, CEO of the Sargent & Greenleaf Family of Brands.
  • Before joining Sargent & Greenleaf, Samaan managed direct and indirect procurement for Fresenius Kabi in Lake Zurich, Illinois.
  • To learn more about Sargent and Greenleaf, please visit http://www.SargentAndGreenleaf.com
    SOURCE Sargent & Greenleaf Inc.

Fresenius Kabi Announces Availability of Acetaminophen Injection for Intravenous use in Ready-to-Use freeflex® Bags

Retrieved on: 
Thursday, December 10, 2020

Fresenius Kabi announced today the immediate availability in the United States of acetaminophen injection in freeflex bags.

Key Points: 
  • Fresenius Kabi announced today the immediate availability in the United States of acetaminophen injection in freeflex bags.
  • View the full release here: https://www.businesswire.com/news/home/20201210005058/en/
    Fresenius Kabi launches acetaminophen injection in freeflex bags in the U.S. (Photo: Business Wire)
    Acetaminophen injection is used in the hospital setting for pain management and fever reduction.
  • Acetaminophen injection is available in 1,000 mg per 100 mL freeflex bags, a preferred delivery system that helps to promote safety and convenience.
  • Fresenius Kabi freeflex bags are preferred delivery systems that are clear, non-PVC, non-DEHP and made without natural rubber latex.

Fresenius Kabi and Kit Check Collaborate on RFID Compatibility

Retrieved on: 
Wednesday, December 9, 2020

Fresenius Kabi and Kit Check today announced the companies have entered into an agreement under which Fresenius Kabi +RFID medications will be read by the Kit Check inventory management solution.

Key Points: 
  • Fresenius Kabi and Kit Check today announced the companies have entered into an agreement under which Fresenius Kabi +RFID medications will be read by the Kit Check inventory management solution.
  • We are delighted to be partnering with Fresenius Kabi as part of our ongoing mission to increase interoperability across the pharmaceutical supply chain, said Kevin MacDonald, CEO and co-founder of Kit Check.
  • As part of Fresenius Kabis collaboration with Kit Check, +RFID medications, beginning with the anesthetic Diprivan (propofol), will be able to be read in the Kit Check system, allowing customers to access all of the relevant information for reliable product tracking.
  • In 2021, Fresenius Kabi expects to add more than 20 medicines to its +RFID portfolio in the United States.